An update from Benitec Biopharma Ltd (BNTC) is now available.
Benitec Biopharma Inc. announced promising interim results from its BB-301 Phase 1b/2a clinical trial, capturing the attention of the stock market and investors. The company is set to share these findings during a live virtual R&D event on April 18, 2024, stirring interest among stakeholders and potential investors looking for groundbreaking developments in the biopharmaceutical sector.
See more data about BNTC stock on TipRanks’ Stock Analysis page.
